Dorr VJ. A practitioner's guide to cancer related alopecia. Semin Oncol 1998, 25, 562-570
Piérard GE, Paquet P, Piérard-Franchimont C, Rorive A, Quatresooz P. Réactions cutanées indésirables à la chimiothérapie et leurs traitements. Rev Med Liège 2007, 62, 457-462
Hinds G, Thomas VD. Malignancy and cancer treatment-related hair and nail changes. Dermatol Clin 2008, 26, 59-68
Velez N, Khera P, English JC. Eyebrow loss: clinical review. Am J Clin Dermatol 2007, 8, 337-346
Wagner L, Bye GM. Body image and patients experiencing alopecia as a result of cancer chemotherapy. Cancer Nurs 1979, 2, 365-369
Hilton S, Hunt K, Emslie C, Salinas M, Ziebland S. Have men been overlooked? A comparison of young men and women's experiences of chemotherapy induced alopecia. Psychooncology 2008, 17, 77-83
Lavker RM, Miller S, Wilson C, Cotsarelis G, Wei ZG, Yang JS, Sun TT. Hair follicle stem cells: their location, role in hair cycle and involvement in skin tumor formation. J Invest Dermatol 1993, 101, 16S-26S
Hutchinson PE, Thompson JR. The size and form of the medulla of human scalp hair is regulated by the hair cycle and cross-sectional size of the hair shaft. Br J Dermatol, 1999, 140, 438-445
Elliot K, Stephenson TJ, Messenger AG. Differences in hair follicle dermal papilla volume are due to extracellular matrix volume and cell number: implications for the control of hair follicle size and androgen responses. J Invest Dermatol, 1999, 113, 873-877
Stenn KS, Nixon AJ, Jahoda CAB, McKay IA, Paus R. What controls hair follicle cycling? Exp Dermatol 1999, 8, 229-236
Piérard-Franchimont C, Piérard GE. Comment j'explore...une perte de cheveux chez un patient cancéreux. Rev Med Liège 2004, 9, 525-529
Piérard-Franchimont C, Piérard GE. Teloptosis, a turning point in hair shedding biorythms. Dermatology, 2001, 203, 115-117
Milner Y, Sudnik J, Filippi M, Kizoulis M, Kashgarian M, Stenn K. Exogen, the shedding phase of the hair cycle growth cycle: characterization of a mouse model. J Invet Dermatol 2002, 119, 639-644
Piérard-Franchimont C, Piérard GE. A propos du follicule pileux et du cycle pilaire: considérations récentes. Rev Med Liège 1997, 52, 671-674
Courtois M, Loussouarn G, Hourseau C, Grollier JF. Hair cycle and alopecia. Skin Pharmacol 1994, 7, 84-89
Piérard-Franchimont C, Petit L, Loussouarn G, et al. The hair eclipse phenomenon: sharpening the focus on the hair cycle chronobiology. Int J Cosmet Sci, 2003, 25, 295-299
Rebora A, Guarrera M. Kenogen: a new phase of the hair cycle? Dermatology, 2002, 205, 108-110
Piérard GE, Piérard-Franchimont C, Marks R, et al. EEMCO guidance for the assessment of hair shedding and alopecia. Skin Pharmacol Physiol 2004, 17, 98-110
Price V, Gummer C. Loose anagen syndrome. J Am Acad Dermatol 1989, 20, 249-256
Headington JE. Telogen effluvium: new concepts and review. Arch Dermatol 1993, 29, 56-63
Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle aged women. J Am Acad Dermatol 1996, 35, 898-906
Piérard-Franchimont C, Piérard GE. Paroxysmal reactions of the scalp. Rev Med Liège, 2004, 59, 180-185
Quatresooz P, Piérard-Franchimont C, Arrese JE, Rorive A, Piérard GE. Comment j'explore... une métastase cutanée. Qui es-tu? d'où viens-tu? Rev Med Liège 2008, 63, 559-563
Trüeb RM, Krasovec M. Erosive pustular dermatosis of the scalp following radiation therapy for solar keratoses. Br J Dermatol 1999, 141, 763-765
Henry F, Xhauflaire-Uhoda E, Piérard GE. Prévention et traitement des radiodermites. Skin 11, 140-143, 2008
Botchkarev VA, Komarova EA, Siebenhaar F et al. p53 is essential for chemotherapy-induced hair loss. Cancer Res, 2000, 60, 5002-5006
Piérard-Franchimont C, Quatresooz P, Berardesca E, Plomteux G, Piérard GE. Environmental hazards and the skin. Eur J Dermatol 2006, 16, 322-324
Selleri S, Arnaboldi F, Palazzo M, Hussein U, Balsari A, Rumio C. Caveolin-1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy. Br J Dermatol, 2005, 153, 506-513
Hendricx S, Handjiski B, Peters EMJ, Paus R. A guide to assessing damage response pathways of the hair follicle: lessons from cyclosphamide-induced alopecia in mice. J Invest Dermatol 2005, 125, 42-51
Bodo E, Tobin DJ, Kamenisch Y, Biro T, Berneburg M, Funk W, Paus R. Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy. Am J Pathol 2007, 171, 1153-1167
Litt JZ. Drug eruption reference manual. 9th ed New York: Parthenon Publishing Group Inc, 2003
Lombardi D, Crivellari D, Scuderi C, et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumor, 2004, 90, 285-288
Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol, 2006, 7, 45-63
Fontana JA. Radiation recall associated with VP-16-213 therapy. Cancer Treat Rep, 1979, 63, 224-225
Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of trinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol, 1997, 15, 625-631
Hussein MA, Anderson KC. Role of liposomal anthracyclines in the treatment of multiple myeloma. Semin Oncol, 2004, 31, 147-160
Blumenreich MS, Woodcock TM, Richman SP, et al. A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies. Cancer, 1985, 56, 256-258
Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med, 2001, 46, 110-116
Tosti A, Piraccini BM, Vincenzi C, Misciali C. Permanent alopecia after busulfan chemotherapy. Br J Dermatol 2005, 152, 1056-1058
Machado M, Moreb JS, Khan SA. Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 40, 979-982
Fairlamb DJ. Hair changes following cytotoxic drug induced alopecia. Postgrad Med J, 1988, 64, 907-911
Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowki P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006, 55, 657-670
Gallimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H. Classiciation and mangement of skin, hair, nail, and mucosal side effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007, 43, 845-851
Lacouture ME, Lai SE. The PRIDE (Papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006, 155, 852-854
Deslandres M, Sibaud V, Chevreau C, Delord JP. Effets secondaires cutanés des nouvelles molecules anticancéreuses: focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l'EGF. Ann Dermatol, 2008, 135, S16-S24
Agero AL, Dusza S, Benvenuto-Andrade C, Busam C, Myskowsky P, Halpern A. Dermatologic side effects associated with epidermal growth factor receptor inhibitor. J Am Acad Dermatol, 2006, 55, 657-670
Robert C, Sona JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol, 2005, 6, 491-500
Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002, 147, 598-601
Graves JE, Jones BF, Lind AC, Heffernan MP. Nonscarring inflammatory alopecia associated with the epidermal growth factor inhibitor gefitinib. J Am Acad Dermatol 2006, 55, 349-353
Heymann WR. Epidermal growth factor receptor inhibitors and hair. J Am Acad Dermatol 2008, 58, 642-643
Guillot B, Blazquez L, Bessis D, et al. A prospective study of cutaneous adverse events induced by low dose alpha interferon treatment for malignant melanoma. Dermatology, 2004, 208, 49-54
Fattovich G, Giustina G, Favardo S, Ruol A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol, 1996, 24, 38-47
Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol, 1995, 33, 393-410
Robert C, Soria JC, Spatz A, et al. Cutaneous side effects of kinase inhibitors and blocking antibodies. Lancet Oncol, 2005, 6, 491-500
Robert C. Cutaneous side effects of antiangiogenic agents. Bull Cancer, 2007, 94, S260-S264
Chan CC, Yao M, Tsai TF. Diffuse depigmentation in a patient with chronic myeloid leukaemia. J Am Acad Dermatol, 2006, 54, 738-740
Clarke JT, Price H, Clarke S, et al. Acquired kinking of the hair caused by acitretin. J Drugs Dermatol, 2007, 6, 937-938
Piérard-Franchimont C, Xhauflaire-Uhoda E, Loussouarn G, Saint-Léger D, Piérard GE. Dandruff-associated smouldering alopecia. A chronobiological assessment over 5 years. Clin Exp Dermatol 2006, 31, 23-26
Quatresooz P, Piérard-Franchimont C, Arrese JE, Piérard GE. Clinicopathologic presentations of dermatomycoses in cancer patients. J Eur Acad Dermatol Venereol 2008, 22, 407-417
Slee PHTJ, van der Waal RIF, Schagen van Leeuwen JH, et al. Paraneoplastic hypertrichosis lanuginose acquisita: uncommon or overlooked? Br J Dermatol 2007, 157, 1087-1092
Kerob D, Dupuy A, Reygagne P, et al. Facial hypertrichosis induced by cetuximab and anti-EGF monoclonal antibody. Arch Dermatol, 2006, 142, 1657-1658
Pascual JC, Banuls J, Belinchon I, Blanes M, Massuti B. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol 2004, 151, 1111-1112
Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr 2007, 23, 65-66
Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs, 2006, 22, 152-162
Zhang G, Bati S, Jampol LM. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and review of literature. Cornea, 2007, 26, 858-860
Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol, 2006, 1, 1040-1041
Roe E, Garcia Muret MP, Marcuello E, Capdevila J, Pallares C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol, 2006, 55, 429-437
Kim SY, Choi HJ, Park HJ, Lee JY, Cho BK. An unusual terminal hair growth on the nose tip associated with gefitinib therapy. Br J Dermatol 2007, 156, 1087-1088
Goksugur N, Karabay O. Eyelash and eyebrow trichomegaly induced by interferon ?2a. Clin Exp Dermatol, 2007, 32, 583-584
Richardson LC, Wang W, Hartzema AG, Wagner S. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J 2007; 13: 581-587
Ridderheim M, Bjurberg M, Gustavsson A. Scalp hypothermial to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitalized scalp-cooling system used in 74 patients. Supp Care Cancer, 2003, 11, 317-377
Grevelman EG, Breed WD. Prevention of chemotherapy induced hair loss by scalp cooling. Ann Oncol 2005, 16, 352-358
Spaëth D, Rosso N, Clivot L. Prise en charge de l'alopécie des patients atteints de cancer. Rev Prat 2006, 56, 2020-2024
Hussein AM, Jimenez JJ, McCall CA, et al. Protection from chemotherapy-induced alopecia in a rat model. Science, 1990, 249, 1564-1566
Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J, 1993, 86, 489-496
Hussein AM. Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. Int J Dermatol, 1995, 34, 470-473
Paus R, Böttge JA, Henz BM, Maurer M. Hair growth control by immunosuppression. Arch Dermatol Res 1996, 288, 408-410
Peters EMJ, Foitzik K, Paus R, Ray S, Holick MF. A new strategy for modulating chemotherapy-induced alopecia, using PTH-PTHrP receptor agonist and antagonist. J Invest Dermatol 2001, 117, 173-178
Harmon CS, Nevins TD. Biphasic effect of 1,25-dihydroxyvitamin D3 on human hair follicle growth and hair fiber production in whole-organ cultures. J Invest Dermatol 1994, 103, 318-322
Billoni N, Gautier B, Mahé YF, Bernard BA. Expression of retinoid nuclear receptor superfamily members in human hair follicles and its implication in hair growth. Acta Derm Venereol. 1997, 77, 350-355
Chen G, Baechle A, Nevins TD, Oh S, Harmon C, Stacey DW. Protection against cyclophosphamide-induced alopecia and inhibition of mammary tumor growth by topical 1,25-dihydroxyvitamin D3 in mice. Int J Cancer 1998, 72, 303-309
Hidalgo M, Rinaldi D, Medina G, Griffin T, Turner J, Von Hoff DD. A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. Anticancer Drugs 1999, 10, 393-395
Wang J, Lu Z, Au JL. Protection against chemotherapy induced alopecia. Pharm Res, 2006, 23, 2505-2514
Piérard-Franchimont C, Henry F, Paquet P, Piérard GE. Comment je traite... une hypertrichose. Rev Med Liège 2003, 58, 605-610
